Peking Union Medical Hospital Licenses KPPS Mouse Model for Intraductal Papillary Mucinous Neoplasm Research in $10,000 Technology Transfer Deal
Recently, Peking Union Medical College Hospital released a public notice on the transformation of scientific and technological achievements, proposing to transfer a“Preparation Method and Application of Mouse Models of Intraductal Papillary Mucinous Neoplasm of the Pancreas and Their Tumor Cells”Patent achievements, transferred to Beijing Weitongda Biotechnology Co., Ltd., with a transaction amount of¥100,000. This achievement was made by pancreatic surgery experts at Peking Union Medical College HospitalCui MingLed the research and development as the principal investigator.
Cui Ming:Attending Physician in General Surgery; Postdoctoral Fellow in Clinical Medicine. He received his bachelor’s degree from Peking University Health Science Center and his doctoral degree from Peking Union Medical College. He completed a joint doctoral program at Johns Hopkins University School of Medicine, sponsored by the China Scholarship Council, and served as a Visiting Scholar at NYU Langone Health. He was selected for the PUMC Young Scholars Support Program and the Beijing Association for Science and Technology’s Young Talent Lift Project. He has presided over multiple research projects, including those funded by the National Natural Science Foundation of China and the Beijing Municipal Natural Science Foundation.
The core of this invention lies in providing a model construction method termed the “KPPS mouse,” which, through treatment with an inducer, successfully generates an animal model that fully recapitulates the pathological progression of human intraductal papillary mucinous neoplasm (IPMN) of the pancreas. This model addresses the previous lack of ideal in vivo tools in research, offering an indispensable experimental platform for elucidating the mechanisms underlying IPMN initiation and progression, conducting high-throughput drug screening, and developing novel therapeutic strategies.
Intraductal Papillary Mucinous Neoplasm of the Pancreas, abbreviated as IPMN, is the most common type of pancreatic cystic neoplasm and a known precursor lesion to pancreatic cancer. Its characteristic pathological feature is the formation of branching papillary projections by tumor cells within dilated pancreatic ducts; these cells produce abundant mucin, which often fills the entire ductal lumen.
During the initiation and progression of IPMN, scientists have identified driver gene mutations, including those in KRAS and GNAS, as well as mutations in genes associated with malignant progression, such as TP53 and CDKN2A.
To gain a deeper understanding of how these genetic mutations drive tumorigenesis, researchers have developed various genetically engineered mouse models. These models recapitulate specific genetic alterations in vivo, enabling tumor formation within the native microenvironment of an intact immune system, which is critical for such studies.
Among these, the KPPC mouse model is widely used in pancreatic cancer research; however, it has a critical limitation: the Cre recombinase tool employed lacks ductal cell-specific expression in the pancreas. This means that the model cannot accurately recapitulate the cellular origin of intraductal papillary mucinous neoplasms (IPMNs), thereby limiting its specificity for studying IPMNs and their associated invasive carcinomas.
To build more accurate models, scientists have turned their attention toSox9 Gene, because it is specifically expressed in pancreatic ductal cells of adult mice. Using Sox9-CreER transgenic mice enables precise genetic manipulation of ductal cells. However, studies have shown that activating Kras gene mutations solely in mouse ductal cells is insufficient to induce IPMN formation.
For example, the study by von Figura et al. successfully induced IPMN-like precancerous lesions by concurrently introducing Kras mutations and knocking out the Brg1 gene in ductal cells; however, the lesions in this model appeared to arrest at an early stage, as the study only followed the mice up to 6 weeks of age and failed to observe progression to more advanced stages.
Another study conducted by Janel L. Kopp et al. employed a different strategy, simultaneously activating the Kras mutation and knocking out the Pten gene in ductal cells. This model successfully induced IPMN-like lesions, which ultimately progressed to IPMN-associated invasive carcinoma.
However, this model has a very obvious drawback: its tumor progression is extremely slow. Researchers can only observe significant tumor formation when the mice reach 6 to 14 months of age, and such a long cycle greatly limits its application efficiency in experiments that require rapid validation.
Therefore,Develop an animal model that accurately simulates the ductal cell origin of IPMN and comprehensively recapitulates its entire progression from precancerous lesions to invasive carcinoma within a reasonable timeframe., has become a critical bottleneck urgently requiring breakthrough in this research field.
Addressing the deficiencies and pain points in IPMN treatment, the KPPS mouse model developed by this patent demonstrates its core advantages and advancements primarily inUnprecedented Precision Targeting Capability of Disease-Originating Cells. This model innovatively employs the genetic tool Sox9-CreER.
The Sox9 gene is specifically expressed in ductal cells of the adult mouse pancreas; therefore, Cre recombinase driven by its promoter ensures that subsequent genetic manipulations are strictly confined to ductal cells. This design fundamentally recapitulates the cytological essence of human intraductal papillary mucinous neoplasm (IPMN) as a tumor originating from ductal epithelium, representing a fundamental departure from previous models constructed using non-specific tools such as Pdx1-CreER (which is expressed in both pancreatic acinar and ductal cells), thereby ensuring the anatomical accuracy of the induced lesions.
Based on precise targeting, the modelTamoxifenFenDrug-induced simultaneous initiation of the two most critical genetic events in ductal cells:Activation of the Kras G12D oncogenic mutation and knockout of the Trp53 tumor suppressor gene.This combination mimics the classic synergy of driver genes in human pancreatic carcinogenesis.
Its genetic manipulation design is extremely sophisticated: prior to induction, the mutant Kras gene is silenced by a sequence known as LSL (LoxP-Stop-LoxP), while loxP sites are inserted on both sides of the Trp53 gene. Upon tamoxifen-induced activation of Cre recombinase, the enzyme precisely recognizes and cleaves these loxP sites, thereby simultaneously removing the stop signal upstream of the Kras gene to initiate its expression and deleting a critical fragment of the Trp53 gene to abolish its function. This“One-Step Induction, Dual-Gene Modification”mechanism, ensuring that tumor initiation occurs in the correct cells and is driven by the appropriate genes.
The most significant breakthrough advantage of this model lies in its ability to completely and reliably recapitulate the entire continuous dynamic pathological process of IPMN, from precancerous lesions to invasive carcinoma, within a relatively reasonable and operable time window. Experimental data indicate that, following short-term (6-day) tamoxifen induction, the model mice require only4 WeeksThus, a definitive low-grade IPMN lesion can be formed.
Subsequently, the disease progressed according to a predetermined timeline: by approximately week 16, the lesions evolved into high-grade IPMN with more pronounced cellular atypia; meanwhile, starting from week 12, some foci had already breached the basement membrane and developed into IPMN-associated invasive carcinoma. This entire process can be fully observed within 24 weeks. Compared with existing models that require waiting six months or even longer to observe advanced-stage lesions, this approach significantly enhances experimental efficiency and practicality, providing researchers with a comprehensive and coherent temporal platform for studies ranging from early intervention to late-stage treatment.
The stability and reproducibility of the model lay a solid foundation for its application. Data show that the median survival time of mice after induction is approximately 20 weeks, providing sufficient time for long-term mechanistic studies and observation of drug efficacy. More importantly, from the advanced-stage tumors of these model mice, cell lines capable of stable proliferation in vitro can be successfully isolated and established.KPPS Tumor Cell Line. These cells not only retain the marker characteristics of epithelial cells and exhibit robust proliferative activity, but also can be re-transplanted into immunocompetent mice to form subcutaneous tumors.
This provides researchers with a comprehensive technical system spanning in vivo animal models, ex vivo cell models, and xenograft tumor models, offering an invaluable tool for conducting multidimensional, multi-level studies, including exploration of molecular mechanisms, high-throughput drug screening, and research on therapeutic resistance.
In summary, the patented technology achieves this by"Cell-specific targeting," "synergistic intervention of key genes," "controllable induction," and "recapitulation of the complete pathological process"a series of innovative designs, successfully buildingAn Ideal Animal Model Highly Mimicking the Initiation and Progression of Human IPMN and Its Derived Resource Repository。
It not only overcomes the core limitations of previous models—such as prolonged development cycles, imprecise targeting, and incomplete representation of pathological stages—but also provides an indispensable and critical research platform for ultimately conquering the challenges in early diagnosis and treatment of IPMN and even pancreatic cancer, thanks to its systematicity, reliability, and efficiency.
To address the core bottlenecks in current research on IPMN and pancreatic cancer—namely, the lack of precision in animal model targeting, incomplete simulation of pathological processes, and excessively long study cycles—relevant research teams and biotechnology companies are conducting in-depth explorations of disease mechanisms.
BeiGeneFocused on the research, development, and commercialization of anti-tumor drugs, within the company’s robust R&D pipeline,BGB-53038It is a highly anticipated investigational new drug. It is a small-molecule inhibitor targeting the KRAS protein; more specifically, it is a “pan-KRAS inhibitor” designed to simultaneously inhibit multiple KRAS mutants. Its mechanism of action involves suppressing the function of mutant KRAS proteins, thereby blocking the key signaling pathways that drive abnormal growth and proliferation in tumor cells.
Currently, BGB-53038 is in Phase I clinical development. A Phase I clinical trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of BGB-53038 as monotherapy or in combination with tislelizumab (an anti-PD-1 antibody) or cetuximab (an anti-EGFR antibody) entered the patient enrollment phase between late 2024 and early 2025.
Hengrui MedicineSelf-developedHRS-4642 InjectionIt is a targeted anti-tumor drug specifically designed for the KRAS G12D mutant. The drug utilizes a liposomal formulation, and its mechanism of action involves specific binding to the KRAS G12D mutant protein, thereby inhibiting the phosphorylation of key downstream signaling proteins such as MEK and ERK, which blocks the proliferation and growth pathways of tumor cells.
Currently, the development of HRS-4642 has achieved breakthrough progress, and the drug has officially entered Phase III clinical trials for advanced or metastatic pancreatic cancer harboring KRAS G12D mutations.
Currently, research and drug development in this field are primarily constrained by several key bottlenecks. InTargeted TherapyIn this regard, although inhibitors targeting the core driver mutation KRAS G12D have entered clinical trials, how to enhance their efficacy and overcome drug resistance remains an unresolved challenge. InImmunotherapyIn this field, the unique immunosuppressive microenvironment of pancreatic cancer limits the efficacy of monotherapy, making the development of effective combination therapies a key priority. A more fundamental challenge lies in the fact that the vast majority of therapeutic approaches target advanced-stage cancer, while there remains a lack of validated, clinically applicable early intervention strategies for identifiable precursor lesions such as intraductal papillary mucinous neoplasm (IPMN).
Looking ahead, the development of the field will depend closely on advances in underlying research tools and innovations in therapeutic concepts. Future treatment paradigms are likely to shift toward “early intervention,” leveraging increasingly precise screening technologies to identify high-risk intraductal papillary mucinous neoplasms (IPMNs) at earlier stages and applying effective local or systemic interventions to prevent their malignant transformation. Ultimately, conquering this disease will likely require the sequential and combinatorial integration of diverse strategies—including targeted therapy, immunomodulation, and local treatments—to establish individualized management plans that span the entire disease course.